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SUMMARY 
Autoantibodies to dense fine speckles 70 (DFS70) are purported to rule out the diagnosis of SLE 
when they occur in the absence of other SLE-related autoantibodies. This study is the first to 
report the prevalence of anti-DFS70 in an early, multi-national inception SLE cohort and 
examine demographic, clinical, and autoantibody associations.  Patients were enrolled in the 
Systemic Lupus International Collaborating Clinics (SLICC) inception cohort within 15 months 
of diagnosis. The association between anti-DFS70 and multiple parameters in 1137 patients was 
assessed using univariate and multivariate logistic regression. The frequency of anti-DFS70 was 
7.1% (95%CI: 5.7-8.8%), while only 1.1% (95%CI: 0.6-1.9%) were monospecific for anti-
DFS70.  In multivariate analysis, patients with musculoskeletal activity (Odds Ratio (OR) 1.24 
[95% CI: 1.10, 1.41]) or with anti-β2 glycoprotein 1 (OR 2.17 [95% CI: 1.22, 3.87]) were more 
likely and patients with anti-dsDNA (OR 0.53 [95% CI: 0.31, 0.92]) or anti-SSB/La (OR 0.25 
[95% CI: 0.08, 0.81]) were less likely to have anti-DFS70. In this study, the prevalence of anti-
DFS70 was higher than the range previously published for adult SLE (7.1 vs 0 - 2.8%) and was 
associated with musculoskeletal activity and anti-β2 glycoprotein 1 autoantibodies. However, 
‘monospecific” anti-DFS70 autoantibodies were rare (1.1%) and therefore may be helpful to 
discriminate between ANA positive healthy individuals and SLE. 
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INTRODUCTION 
Autoantibodies directed against nuclear and other intracellular autoantigens (anti-nuclear 
antibodies: ANA) are commonly used biomarkers for the diagnosis and classification of systemic 
lupus erythematosus (SLE) and other ANA-associated rheumatic diseases (AARD)1,2. Despite 
lacking specificity, the American College of Rheumatology (ACR) has identified the indirect 
immunofluorescence (IIF) ANA test as the diagnostic screening immunoassay of choice for 
AARD3. Of interest, autoantibodies directed against the dense fine speckles 70 (DFS70) nuclear 
antigen represent an apparent ANA paradox because they are reported to be less frequently in 
patients with SLE and other AARD than in apparently healthy individuals or those who do not 
meet diagnostic criteria for AARD{Mahler, 2012 24623 /id;Fitch-Rogalsky, 2014 26100 
/id;Bizzaro, 2015 28210 /id;Nilsson, 2015 28173 /id;Conrad, 2016 29863 /id}. Thus, studies to 
date showing a lower prevalence of anti-DFS70 antibodies in adult patients with SLE compared 
to healthy adults (0-2.8% versus 2.0 -23.2% when anti-DFS70 is assessed by chemiluminescence 
immunoassay [CIA]) suggested that these autoantibodies may serve as biomarkers that 
differentiate ANA positive individuals without an AARD from patients with AARD 
(Supplemental Table 1). A summation of the published studies on the frequency of anti-DFS 
autoantibodies in various adult SLE cohorts is shown in Supplemental Table 2.  
 
In previous studies, when anti-DFS70 antibodies were present in an SLE patient, at least 
one other autoantibody usually accompanied them 4,7,10-12. Only 1 adult SLE patient reported in 
the literature (<0.4% of SLE) was identified to have anti-DFS70 antibodies in isolation (or 
monospecific anti-DFS70 antibodies) 4. On the other hand, the frequency of monospecific anti-
DFS70 autoantibodies in ANA positive apparently healthy patients was reported to be as high as 
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18.8% when assessed by CIA 5. Hence, the presence of monospecific anti-DFS70 antibodies was 
proposed as an exclusion criterion for the diagnosis and classification of SLE 13. 
 To date, there have been no studies examining the frequency of anti-DFS70 antibodies in 
an inception cohort of adult onset SLE. The ability to reliably discriminate SLE from ANA-
positive individuals without AARD at onset of signs and symptoms could be an important tool 
that has diagnostic, socioeconomic and other implications, which include avoiding additional 
unnecessary investigations and undue anxiety among patients and physicians 14.  Evidence that 
autoantibodies can be detected years before the clinical onset of SLE 15,16 also raises the 
possibility that anti-DFS70 antibodies can be used as a prognostic discriminator for ANA 
positive individuals. The present study is the first to determine the frequency of anti-DFS70 
antibodies and associations with demographic, clinical and serological features in a large 
international cohort of newly diagnosed SLE patients. 
 
MATERIALS AND METHODS 
Study Design and Setting 
This study was performed using data and patient sera collected through the Systemic Lupus 
Erythematosus International Collaborating Clinics (SLICC) inception cohort 17,18. Between 1999 
and 2012, investigators from 32 centers in 11 countries enrolled patients fulfilling the ACR 
Classification Criteria for definite SLE 19 within 15 months of diagnosis. The study was 
approved by the Institutional Review Board at each participating site and was performed in 
compliance with the Helsinki Declaration. 
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Clinically defined samples 
Demographic and clinical data were collected at enrollment and included age, gender, 
race/ethnicity, study site, post-secondary education, history of smoking and alcohol 
consumption, presence of hypertension and nephritis, fulfillment of ACR Classification Criteria, 
disease activity, and medication use (Supplemental Table 3). Hypertension was defined as being 
on an anti-hypertensive medication or systolic blood pressure > 140 or diastolic blood pressure > 
90; nephritis was based on renal biopsy or fulfillment of the renal item in the ACR Classification 
Criteria19; disease activity was measured by the SLE Disease Activity Index 2000 [SLEDAI-2K]  
20. 
 
Indirect Immunofluorescence assay (IIF) 
The serum (earliest available on enrollment of each patient) was analyzed by Mitogen Advanced 
Diagnostic Laboratory (University of Calgary, Calgary, Alberta, Canada). Aliquots of the 
anonymized SLE sera obtained from a central biobank were stored at -80oC until required for 
immunoassays. The IIF immunoassay was initially performed at a screening dilution of 1/160 
using the HEp-2000 cell substrate kit (ImmunoConcepts, Sacramento, CA) and fluorescein 
(FITC) conjugated to anti-human IgG (H + L) according to the manufacturer’s instructions. 
Taking differences in the performance of HEp-2 ANA IIF assays from different manufacturers 
into consideration 21, ANA were also performed on serum samples with discrepant IIF and 
DFS70 CIA results using HEp-2 IIF kits from another manufacturer (Inova Diagnostics Inc., San 
Diego, CA)  and results determined by automated IIF platform (NovaView, Inova Diagnostics 
Inc.) according to the manufacturer’s instructions. IIF results were read by technologists with 
>10 years of experience at Mitogen Advanced Diagnostics as previously described 22. 
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Chemiluminescence anti-DFS70 antibody assays 
All samples were tested for the presence of anti-DFS70 antibodies by CIA (QUANTA Flash, 
Inova Diagnostics Inc.). The assay used purified full length human recombinant DFS70 coated 
onto paramagnetic beads contained in a reagent cartridge which was loaded onto the analyzer 
(BioFlash, Inova Diagnostics Inc.). The principles and protocols of the assay have been 
previously described 4. The established cut-off for positive anti-DFS70 antibodies was 
established by Receiver Operator Characteristic (ROC) by the manufacturer (Inova Diagnostics) 
and validated by the diagnostic laboratory (Mitogen) and set at >20 chemiluminescent units 
(CU). Monospecific anti-DFS70 autoantibodies was defined as the presence of anti-DFS70 
antibodies in the absence of anti-double-stranded DNA (dsDNA) and other autoantibodies 
detected in the extractable nuclear antigen (ENA) panel described below. Confirmation of IIF 
DFS70 reactivity was by an absorption immunoassay (HEp-2 Select: Inova Diagnostics Inc.) 
wherein anti-DFS70 reactivity is specifically removed from positive sera using methods as 
previously described 23. 
 
Detection of anti-dsDNA and other autoantibodies  
Anti-dsDNA antibodies were quantified using a CIA (Inova Diagnostics Inc.) using the same 
approach as described above for anti-DFS70 antibodies. Antibodies to PCNA, ribosomal-P, 
Ro52/TRIM21, SSA/Ro60, SSB/La, Sm, and U1-RNP were detected using the ENA FIDIS 
Connective Profile kit 13 addressable laser bead immunoassay array (ALBIA: TheraDiag, Paris, 
France) using a Luminex 200 flow luminometer (Luminex, Austin, TX). All assays were 
performed according to the manufacturer’s instructions. Briefly, anti-human IgG coupled to 
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phycoerythrin was added to samples and was read on the Luminex 200 system using the MLX-
Booster software. Samples were classified as negative at <30 arbitrary units (AU)/mL, weakly 
positive 30-49 AU/mL, moderately positive 50-80AU/mL, and strongly positive >81AU/mL. 
Other autoantibodies such as IgG anti-cardiolipin, IgG anti-β2 glycoprotein 1, and lupus 
anticoagulant were measured in a central laboratory as previously described 24. 
 
Statistical Evaluation 
Statistical analysis was performed using Stata 14.1 (StataCorp, College Station, TX, USA).  
Univariate and multivariate logistic regression analyses were used to examine potential 
predictors of the odds of having anti-DFS70 antibodies.  Potential predictors included: age at 
diagnosis, disease duration, gender, race/ethnicity, post-secondary education, smoking, alcohol 
use, hypertension, nephritis at enrolment, ACR Classification Criteria fulfilled (total and 
individual), SLEDAI-2K (global score and organ system scores), medications (steroids, anti-
malarials, immunosuppressive agents), ANA, anti-dsDNA, ENA panel, IgG anti-cardiolipin, IgG 
anti-β2 glycoprotein 1, and lupus anticoagulant. For the most informative multivariate model, 
only the remaining statistically significant predictors at the 95% confidence interval (CI) were 
included, after eliminating all other potential predictors individually, starting with the least likely 
to be associated with the outcome. 
Although we were interested in measuring regional variation, we did not include the 
different study sites in the primary model as it was correlated with some clinical and serological 
features.  Hence, we have conducted a secondary analysis where the study site is included in 
addition to the other variables included in the primary model. 
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RESULTS 
1137 patients were enrolled in the study with a mean age of 35.1 years at diagnosis, a 
mean duration of 0.47 years; 1022 (89.9%) were female, 511/1130 (45.2%) were of non-White 
ethnic background, and 724/1085 (66.7%) had obtained post-secondary education (Table 1). 
Three hundred and twelve of 1084 or approximately 29% of the cohort had nephritis at 
enrolment, the mean global SLEDAI-2K was 5.3, and 80.3% reported a history of steroid use, 
73.6% antimalarial use, and 42.6% immunosuppressant use other than biologics.  
The frequency of anti-DFS70 autoantibodies as detected by CIA was 7.1% or 81/1137 
(95% CI: 5.7, 8.8%) but by contrast, 13/1137 or 1.1% (95% CI: 0.6, 1.9%) were monospecific 
positive for anti-DFS70 (Table 1).  Approximately 94% (1066/1137) of the entire cohort had a 
positive ANA by IIF on HEp-2000 substrate; 6.2% (5/81) of the anti-DFS70 positive sera by 
CIA had a negative ANA by IIF and 6.3% (66/1056) of the anti-DFS70 negative sera had a 
negative ANA by IIF, both on HEp-2000 substrate. The anti-DFS IIF pattern was observed in 
12.3% (10/81) of patients with an anti-DFS70 by CIA and in 0.7% (7/1056) of those without an 
anti-DFS70 by CIA. Only 15.4% (2/13) of the monospecific anti-DFS70 positive sera had a DFS 
IIF pattern. Of the 5 sera that were anti-DFS70 positive but ANA negative on HEp-2000 
substrate and retested on HEp-2 cells from another manufacturer (see Methods), 4 were found to 
have a positive ANA. When the 10 sera that were positive for anti-DFS70 by CIA and had the 
typical IIF DFS pattern were tested by the IIF absorption immunoassay, one serum demonstrated 
complete abolition of the ANA IIF staining pattern. The IIF staining patterns after absorption 
included nuclear speckled, centromere, nuclear dots, chromosome coat protein, centrosome, and 
cytoplasmic speckled, indicating that the majority of these sera were not monospecific for anti-
DFS70 autoantibodies.  When testing for the conventional SLE-related autoantigen targets using 
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ALBIA, the most common autoantibodies in the DFS70 positive sera were SSA/Ro60 (34.6%), 
followed by Ro52/TRIM21 (27.2%) and dsDNA (26.3%).  
There were no significant differences in age, disease duration, gender, race/ethnicity, 
education level, smoking, alcohol consumption, presence of hypertension, nephritis, mean 
number of ACR Classification Criteria fulfilled, the global SLEDAI-2K, and medication usage 
(including duration of current and previous doses of immunosuppressive) between the anti-
DFS70 negative and positive patients (Table 1). The anti-DFS70 negative patients had a lower 
mean score on the musculoskeletal items of the SLEDAI-2K (i.e. arthritis and myositis) 
compared the anti-DFS70 positive patients (0.8 vs 1.5).  The anti-DFS70 negative patients had a 
higher frequency of anti-dsDNA (40.1% vs. 26.3%), anti-SSA/Ro60 (46.3% vs. 34.6%), anti-
SSB/La (16.0% vs. 4.9%), anti-U1-RNP (31.5% vs. 21.0%), but a lower frequency of anti-β2 
glycoprotein 1 (14.3% vs. 24.7%). Also, the percentage of patients from the United States was 
lower among the anti-DFS70 negative patients (25.2% vs. 46.9%). 
In the primary multivariate analysis, patients with musculoskeletal activity (based on the 
SLEDAI-2K) (Odds Ratio (OR) 1.24 [95% CI: 1.10, 1.41]) or with anti-β2 glycoprotein 1 (OR 
2.17 [95% CI: 1.22, 3.87]) were more likely to have anti-DFS70 antibodies, while those with 
anti-dsDNA (OR 0.53 [95% CI: 0.31, 0.92]) or anti-SSB/La (OR 0.25 [95% CI: 0.08, 0.81]) 
were less likely to have anti-DFS 70 antibodies (Table 1). 
In a secondary multivariate analysis examining factors associated with anti-DFS 70 
antibodies, which included study site location as a predictor (in addition to the variables 
specified in the primary model), patients from Canada (OR 0.39 [95% CI: 0.20, 0.73]) or Europe 
(OR 0.47 [95% CI: 0.25, 0.88) were less likely to have anti-DFS70 antibody than patients 
residing in other countries and patients of African descent (OR 0.36 [95% CI: 0.14, 0.91])  were 
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also less likely to have anti-DFS70 antibody than those who were not of African descent. As in 
the primary multivariate model, patients with musculoskeletal activity (OR 1.23 [95% CI: 1.08, 
1.40]) or with anti-2 glycoprotein 1 autoantibodies (OR 2.24 [95% CI: 1.25, 4.02]) were more 
likely and those with anti-SSB/La (OR 0.23 [95% 0.07, 0.74]) were less likely to have anti-
DFS70 autoantibodies.  In contrast to the primary model, those with neurological activity (based 
on the SLEDAI-2K) were also more likely to have anti-DFS 70 (OR 1.13 [95% CI: 1.0, 1.27]) 
and anti-ds DNA was no longer associated with the outcome. 
 
DISCUSSION 
Our study is the largest published to date on the prevalence of anti-DFS70 antibodies in a 
newly diagnosed, multi-national and multi-ethnic SLE cohort. Anti-DFS70 antibodies were first 
reported in a patient with interstitial cystitis 25 and were later found to be associated with other 
conditions including atopic dermatitis, Vogt Koyanagi Harada syndrome 26, and prostate cancer 
27. In these early studies, anti-DFS70 autoantibodies were initially identified by IIF screening on 
HEp-2 cells and then confirmed by immunoblotting. The DFS70 nomenclature refers to the IIF 
staining pattern characterized by uniformly distributed fine speckles throughout the interphase 
nucleus and on metaphase chromatin along with the autoantigen target having a molecular mass 
of 70kDa in immunoblots 26. DFS70, also termed lens epithelium derived growth factor 
(LEDGF), has a number of functions, including serving as a cofactor for human 
immunodeficiency virus replication 28, but is also a stress oncoprotein as evidenced by its 
overexpression in diverse human malignancies 29, its association with cell aggression and 
survival, enhancement of resistance to cellular stress {28034} and its role as the DNA-binding 
transcription coactivator p75 31. 
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The present study used a CIA to examine the frequency of anti-DFS70 and determine 
associations between the presence of this autoantibody and demographic, clinical, and 
serological characteristics. We report that the prevalence of anti-DFS70 antibodies detected by 
CIA was higher than that in other previously published adult SLE cohorts (7.1% versus 0-2.8%). 
The frequency of monospecific anti-DFS70 autoantibodies as detected by CIA was also higher 
than previously reported (1.1% versus 0-0.4%), but is still relatively rare.  However, among the 
10 sera that were anti-DFS 70 positive by both CIA and IIF, when an absorption immunoassay 
that specifically removed anti-DFS70 reactivity was used 23, only one serum was found to be 
monospecific because anti-DFS70 sera positive by IIF and negative for immunoassays for SLE-
related autoantibodies had other autoantibodies directed to a variety of intracellular targets.  
Further, we observed that those with higher musculoskeletal scores on the SLEDAI-2K and with 
anti-β2 glycoprotein 1 were more likely to have anti-DFS70 antibodies by CIA whereas those 
with anti-dsDNA and anti-SSB/La were less likely to have anti-DFS70 antibodies.   
In previous reports, the presence of monospecific anti-DFS70 antibodies has been 
proposed as a criterion to exclude the diagnosis of SLE and other AARD (reviewed in (32).  The 
reasons for this apparent autoantibody paradox are still unclear but may be related to 
demographic, genetic, ethnic and environmental factors, concurrent medical therapies, or even 
misdiagnosis 4,13. In a recent North American study of 743 children with AARD and related 
conditions, the overall frequency of anti-DFS70 antibodies in SLE children was 5.7% and 
monospecific anti-DFS70 antibodies were observed in 1.8% 11. Of note, none of the American 
SLE children had anti-DFS70 antibodies compared to >10% of the Canadian SLE children, 
raising the possibility that variability in age, geographic, ethnic/racial, environmental and other 
factors may be involved in the B cell anti-DFS70 autoantibody response. In contrast, in the 
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present study we observed that adult patients from Canada were less likely to have anti-DFS70 
autoantibodies; patients from Europe or of Black descent were also less likely to have anti-DFS 
70.  Although we were unable to verify the findings, another study reported a higher frequency 
of anti-DFS70 antibody in females 33 and in younger subjects 33,34. More studies are needed to 
better understand the demographic, geographical and racial/ethnic factors involved. 
Our finding that patients with higher musculoskeletal SLEDAI-2K scores were more 
likely to have anti-DFS70 autoantibodies whereas those with anti-dsDNA were less likely to 
have anti-DFS70 autoantibodies suggests that SLE patients with anti-DFS70 antibodies tend to 
have milder disease.  Like certain other autoantibodies 35, anti-DFS70 antibody may have a 
protective effect where the titers of the autoantibody might paradoxically increase with disease 
remission 4,36. A study of 251 adult SLE patients also reported lower disease activity in the anti-
DFS70 antibody positive SLE patients 4 and in another report, increasing anti-DFS70 antibody 
levels were associated with disease remission in patients with amyopathic dermatomyositis 
complicated by interstitial lung disease36. However, it seems unlikely that lower disease activity 
is an explanation for the higher frequency of anti-DFS70 observed in our inception cohort. SLE 
patients at disease diagnosis would be expected to have more active disease than those with more 
established treated disease. Hence, the frequency of anti-DFS70 would be expected to be lower 
at disease onset and may increase with disease duration. Although we did not observe that anti-
DFS70 antibodies were less prevalent in patients with other indicators of active disease, such as a 
higher global SLEDAI-2K score or nephritis, it would be of interest to study the inception cohort 
longitudinally to determine if anti-DFS70 antibodies change with disease activity, damage 
accrual, and/or therapeutic interventions.  
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To our knowledge, an association between anti-DFS70 antibody and anti-2GP1 has not 
been previously published although anecdotal evidence suggested there was no association 
between the two autoantibodies 37. In the report by Muro et al. 10, anti-cardiolipin autoantibodies 
were observed in 2/7 anti-DFS70 positive SLE patients and 1/7 had a lupus anticoagulant.  
Although the study design was challenged 37, a more recent report of 421 patients with anti-
DFS70 antibodies with various conditions (12.4% had SLE), thrombosis and/or obstetric 
complications occurred at a higher prevalence compared to healthy blood donors (13.1 % vs. 
3.0%) leading the authors to conclude that anti-DFS70 antibodies may be associated with a 
hypercoagulable state 38.  
It is likely that technical aspects of anti-DFS70 autoantibody detection may also account 
for differences observed in different studies 4,13 (Supplemental Table 1).  We used a state of the 
art, validated CIA that utilizes highly purified human DFS-70 4. It is now recognized that the 
accurate detection of the DFS ANA IIF pattern, particularly in sera with mixed IIF patterns 
composed of DFS and other clinically relevant ANA patterns, poses a significant technical 
challenge 9,39. For example, in our study only 12.3% of those with anti-DFS70 by CIA were 
classified as having a typical anti-DFS pattern by IIF.  The failure to detect anti-DFS accurately 
in the SLE serum is likely due to a masking effect of other autoantibodies on the DFS IIF pattern 
where one dominant pattern may obscure identification of other patterns 6. However, even 
among the monospecific anti-DFS70 antibody patients (13 of 1137; 1.1%), only 15.4% (2/13) 
had a DFS IIF pattern. In addition, when the five samples with a negative HEp-2000 ANA IIF 
test but a positive anti-DFS70 by CIA were retested using another manufacturer’s HEp-2 
substrate, we found that all except 1 of these sera had a positive ANA test. This apparent 
discrepancy is in keeping with a recent report that substantial variation in ANA positivity in SLE 
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cohorts is highly dependent on which ANA kit is chosen for the study 21.  Thus, it is becoming 
clear that the detection of anti-DFS70 antibodies by IIF is dependent on the performance of 
different manufacturer’s kits and using IIF alone underestimates the frequency of this 
autoantibody 9,37. Accordingly, it is imperative that DFS-specific immunoassays such as 
immunoblot 40, immunoabsorption 23, enzyme linked immunosorbent assay (ELISA) 41 and/or 
CIA 6,23 should be used to confirm the presence of anti-DFS70 antibodies before definitive 
results are reported. An advantage of our study, even though samples were retrieved from 
different centers, is that all samples were processed in one laboratory with the same standardized 
immunoassay and interpreted by a single highly trained technologist.  
In addition, there is mounting evidence that anti-DFS detected by IIF may be attributable 
to more than one target autoantigen (i.e. a molecular ligand of DFS70). This is potentially 
reflected in our observation that 0.7% of sera negative for anti-DFS 70 by CIA were anti-DFS 
positive by IIF but did not have detectable anti-DFS70 by CIA. Other antibodies such as those 
directed to methyl CpG binding protein 2 (Mecp2) gave a staining pattern that is 
indistinguishable from anti-DFS70 40, although a study reported that Mecp2 did not react with 
DFS sera as detected by IIF 42 and in our hands these sera also did not bind to Mecp2 (data not 
shown). Hence, future studies will likely focus on other DFS70 ligands.   
 Our study is limited in that we did not use the anti-DFS CIA to study a comparator group 
of ANA positive subjects who were healthy and did not have an AARD.  Comparing the 
prevalence of anti-DFS70 between these two groups is necessary to determine if anti-DFS70 can 
be used to rule out SLE and other AARD in patients who are referred to a rheumatologist 
because they have a positive ANA 5,14. Furthermore, we did not perform statistical correction for 
multiple comparisons, which is consistent with the exploratory and hypothesis generating aspects 
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of our study. However, even after Bonferroni adjustment in both multivariate models, positive 
associations with the musculoskeletal component of the SLEDAI-2K (OR 1.24, adjusted CI: 
1.06, 1.46 in the primary model; OR 1.23, adjusted CI: 1.03, 1.47 in the secondary) and with 
anti-2GP1 (OR 2.17, adjusted CI: 1.04, 4.53 in the primary model; OR 2.24, adjusted CI: 1.01, 
4.99 in the secondary) remained statistically significant, as well as the negative association with 
residing in Canada in the secondary model (OR 0.39, adjusted CI 0.16, 0.92). Thus, while other 
effects included in these models may be subject to further confirmation, these three predictors 
remain quite robust. On the other hand, our study has several advantages over previous reports as 
it involved a highly characterized, multinational, multi-ethnic inception cohort with a larger 
sample size and serum samples were analyzed in a single laboratory. 
 
SUMMARY 
The prevalence of anti-DFS70 in our inception SLE cohort was higher than the range previously 
published for adult SLE (7.1% vs. 0-2.8%) and was associated with a higher musculoskeletal 
SLEDAI-2K score and anti-β2 glycoprotein 1. It is, however, lower than in ANA positive 
healthy adults (23.2%) as reported by other studies. Similarly, the frequency of ‘monospecific’ 
anti-DFS70 autoantibodies (1.1%) was higher than in other adult SLE cohorts (0-0.4%), but it 
was still substantially lower than in ANA positive healthy adults (18.8%) that was seen in prior 
studies. Therefore, monospecific anti-DFS70 may provide a potentially useful way to 
discriminate between SLE and ANA positive individuals that are either healthy or have other 
non-AARD conditions. Further, if a patient has monospecific anti-DFS70 autoantibodies, in the 
setting of possible SLE or other AARD, this should not be considered as a criterion for 
classification or diagnostic purposes. From a technical perspective, reading and interpreting the 
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IIF DFS pattern can be challenging and, hence, autoantigen specific immunoassays that employ 
purified DFS70 or absorption immunoassays are highly recommended in the diagnostic 
laboratory setting. Additional studies of large cohorts of patients are required to confirm these 
and other clinical findings such as disease duration and the impact of therapeutic intervention on 
the B-cell anti-DFS70 response 37.  
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